Vital Innovations Holdings Limited confirmed that trading in its shares has been suspended since 1 April 2026 after its independent auditors issued a disclaimer of opinion on the 2025 annual results. The auditors cited three key uncertainties: the Group’s ability to continue as a going concern, and the recoverability of both prepayments and deposits as well as trade receivables.

On 22 April 2026, the Stock Exchange of Hong Kong delivered formal resumption guidance requiring Vital Innovations to:

1. Eliminate the conditions that led to the audit disclaimer and provide investors with adequate financial disclosure. 2. Demonstrate compliance with Listing Rule 13.24, confirming the company has sufficient operations and asset backing. 3. Release all material information needed for shareholders and investors to appraise the company’s position.

Under Listing Rule 6.01A(1), the Exchange may cancel a listing if trading remains suspended for 18 consecutive months. For Vital Innovations, this remedial window expires on 30 September 2027. Failure to satisfy all resumption conditions by that date will prompt the Listing Division to recommend delisting, though the Exchange retains the discretion to impose a shorter period or proceed with immediate cancellation.

While suspended, Vital Innovations must continue to meet all ongoing obligations, including timely disclosure of inside information, compliance with rules on notifiable and connected transactions, and the publication of periodic financial information. In line with Rule 13.24A, the company must also release quarterly progress updates; the first such report is due on or before 30 June 2026.

The board, chaired by Ms. Rong Xiuli, stated that trading will remain halted until further notice and advised shareholders and potential investors to exercise caution when dealing in the company’s securities.